These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17117594)

  • 1. The critical path initiative: what is in it for P&T Committees?
    Hirschmann JL
    Manag Care Interface; 2006 Oct; 19(10):14. PubMed ID: 17117594
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution of evidence-based medicine and implications for pharmacy & therapeutics committees.
    Williams K
    Manag Care Interface; 2007 Oct; 20(10):6-7. PubMed ID: 18405201
    [No Abstract]   [Full Text] [Related]  

  • 3. P&T committees and proposed device regulation.
    Schmidt AM
    Hosp Formul; 1975 Dec; 10(12):576-8. PubMed ID: 10237823
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges in the anticipation of biosimilars: how must a P&T committee gear up?
    Tadlock C
    Manag Care Interface; 2007 Apr; 20(4):12, 14. PubMed ID: 17536251
    [No Abstract]   [Full Text] [Related]  

  • 5. P & T Committee roundtable discussion: Eastern region Pt. II.
    Fine DJ; Guild RT; Kleinmann K; Kupersmith J
    Hosp Formul; 1984 Jul; 19(7):561-4, 568-70. PubMed ID: 10267389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolutionary role of the pharmacy and therapeutics committee in technology assessment.
    Mehr SR
    Manag Care Interface; 2006 Jan; 19(1):42-5. PubMed ID: 16453995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P & T Committee roundtable discussion: Eastern region. Part I.
    Fine DJ; Guild RT; Kleinmann K; Kupersmith J
    Hosp Formul; 1984 Jun; 19(6):469-72, 475-6. PubMed ID: 10266565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: Good news.
    Am Fam Physician; 1974 Nov; 10(5):71, 73. PubMed ID: 4423090
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug selection: one overlooked aspect.
    Wertheimer AI
    Hosp Formul; 1976 Jun; 11(6):315-6. PubMed ID: 10236468
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
    Karsdal MA; Henriksen K; Leeming DJ; Mitchell P; Duffin K; Barascuk N; Klickstein L; Aggarwal P; Nemirovskiy O; Byrjalsen I; Qvist P; Bay-Jensen AC; Dam EB; Madsen SH; Christiansen C
    Biomarkers; 2009 May; 14(3):181-202. PubMed ID: 19399662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
    Cross M
    Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
    [No Abstract]   [Full Text] [Related]  

  • 12. Rational drug use (II): Hospital drug and therapeutics committees.
    Manyemba J; Dzuda C; Nyazema NZ
    Cent Afr J Med; 2000 Sep; 46(9):256-9. PubMed ID: 11320773
    [No Abstract]   [Full Text] [Related]  

  • 13. P & T committees and the hospital formulary.
    Evans PJ; Standish RC; Bell JE
    Hosp Formul; 1983 Sep; 18(9):892-5. PubMed ID: 10262367
    [No Abstract]   [Full Text] [Related]  

  • 14. [International formula for oleandomycin].
    Lightbown JW; Kogut M; Mussett MV
    Bol Oficina Sanit Panam; 1967 Feb; 62(2):157-65. PubMed ID: 4233668
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence-based decision making in managed care pharmacy.
    Penna P
    Manag Care Interface; 2002 May; 15(5):43-4. PubMed ID: 12024870
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythromycin estolate to remain on market.
    FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171
    [No Abstract]   [Full Text] [Related]  

  • 17. The DERP: is it an effective methodology?
    Heaton AH
    Health Aff (Millwood); 2006; 25(4):W276-8. PubMed ID: 16757488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development.
    Woodcock J
    Clin Pharmacol Ther; 2009 Jul; 86(1):12-4. PubMed ID: 19536116
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug committees should be abolished because the reality has changed].
    Jönsson B; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Mar 14-20; 102(11):880-1; discussion 882-3. PubMed ID: 15835525
    [No Abstract]   [Full Text] [Related]  

  • 20. The latest word from the FDA: an exclusive interview with the commissioner. Interview by John A. Owen Jr.
    Hayes AH
    Hosp Formul; 1982 Aug; 17(8):1063-8, 1075. PubMed ID: 10256696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.